ABSTRACT.We assessed the role of single nucleotide polymorphisms (SNPs) in ERCC1 and ERCC2 genes in the clinical outcomes for osteosarcoma patients receiving cisplatin-based treatment. A perspective study was conducted on 260 patients with osteosarcoma during 2010 and 2011. A polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was used to assess the ERCC1 rs11615 and rs3212986, and the ERCC2 rs1799793 and rs13181 gene polymorphisms. After adjustment for clinical variables, we found that the CC genotype of ERCC1 rs11615 was significantly associated with better response to chemotherapy (OR = 2.87, 95%CI = 1.24-6.97). Our study found that those carrying the CC genotype of ERCC1 rs11615 had a longer overall survival compared with the TT genotype, and the OR (95%CI) was 0.35 (0.12-0.92). In conclusion, our results suggest 11236 Q. Zhang et al. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 11235-11241 (2015) that the ERCC1 rs11615 polymorphism might influence the response to cisplatin-based chemotherapy and affect the clinical outcome for osteosarcoma patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.